Korean Stock Flows

Hanall Biopharma (KRX: 009420)

한올바이오파마 KOSPI Biotech & Pharma 의약품 제조업
Close (Oct 13, 2026)
₩41,950
-2.78%
Market cap
₩2T ($1.6B)
52-week range
₩32,600 – ₩73,000
P/E (12M fwd) · P/B · Div yield
2,985.13 · 13.18 · 0%
trailing – · consensus of 2 analysts

Who is buying Hanall Biopharma?

Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net bought ₩17.3bn ($13M) of Hanall Biopharma, the 34th largest foreign net purchase among 832 KOSPI stocks. Institutions net sold ₩36.8bn ($28M) and retail investors net bought ₩19.9bn ($15M) over the same window. Foreigners were net buyers on 14 of the 20 sessions.

Foreign investors hold 4.46% of Hanall Biopharma's listed shares (KRX ownership data as of Oct 13, 2026), up from 3.94% twenty sessions earlier and 4.75% a year ago.

The stock closed at ₩41,950 on Oct 13, 2026: -22.74% over 20 sessions, -4.11% year-to-date, +21.59% over one year. The 52-week range is ₩32,600 – ₩73,000.

At ₩41,950 the stock trades at 2,985.13× 12-month-forward consensus earnings (2 analysts), 359.35× on FY2027 estimates.

Hanall Biopharma share price, last 60 trading days (KRW)
66,136 56,579 47,021 37,464 Jul 13 Aug 26 Oct 13
Daily foreign investor net purchases, last 60 trading days
+7.2bn +3.6bn -3.6bn -7.2bn Jul 13 Aug 26 Oct 13
View chart data as a table
Date Close Foreign net Institutions Retail
2026-10-13 ₩41,950 +₩3.0bn ₩-1.6bn ₩-2.2bn
2026-10-12 ₩43,150 +₩0.2bn +₩0.2bn ₩-1.1bn
2026-10-08 ₩44,000 +₩1.7bn ₩-1.4bn ₩-0.6bn
2026-10-07 ₩45,800 ₩-2.0bn ₩-1.7bn +₩3.5bn
2026-10-06 ₩47,800 +₩1.8bn +₩1.7bn ₩-2.7bn
2026-10-02 ₩46,100 ₩-5.2bn ₩-1.1bn +₩5.6bn
2026-10-01 ₩48,500 ₩-0.4bn +₩2.8bn ₩-1.7bn
2026-09-30 ₩44,100 +₩3.2bn ₩-2.4bn ₩-0.9bn
2026-09-29 ₩43,250 +₩1.7bn ₩-3.7bn +₩1.5bn
2026-09-28 ₩43,400 +₩1.4bn ₩-5.7bn +₩3.8bn
2026-09-23 ₩46,600 ₩-0.0bn ₩-0.4bn +₩0.2bn
2026-09-22 ₩45,950 ₩-1.1bn ₩-1.3bn +₩2.3bn
2026-09-21 ₩46,800 +₩0.3bn ₩-2.3bn +₩1.9bn
2026-09-18 ₩47,650 ₩-1.1bn ₩-1.4bn +₩2.7bn
2026-09-17 ₩48,150 +₩0.3bn ₩-0.4bn ₩-0.2bn
2026-09-16 ₩47,750 +₩1.6bn ₩-2.3bn +₩0.7bn
2026-09-15 ₩48,600 +₩0.6bn ₩-2.2bn +₩1.6bn
2026-09-14 ₩49,300 +₩2.8bn ₩-2.6bn ₩-0.1bn
2026-09-11 ₩50,100 +₩1.4bn ₩-4.9bn +₩3.6bn
2026-09-10 ₩52,600 +₩7.2bn ₩-5.9bn +₩2.0bn
2026-09-09 ₩54,300 ₩-0.6bn ₩-1.0bn +₩1.5bn
2026-09-08 ₩54,400 +₩1.7bn ₩-3.5bn +₩1.5bn
2026-09-07 ₩55,500 +₩0.9bn ₩-0.2bn ₩-0.7bn
2026-09-04 ₩54,700 ₩-1.2bn +₩0.8bn ₩-0.0bn
2026-09-03 ₩53,900 +₩4.8bn ₩-5.7bn +₩0.9bn
2026-09-02 ₩55,000 +₩4.4bn ₩-0.5bn ₩-4.0bn
2026-09-01 ₩55,100 +₩4.6bn ₩-11.7bn +₩7.0bn
2026-08-31 ₩59,700 ₩-2.5bn ₩-2.3bn +₩5.1bn
2026-08-28 ₩64,600 +₩2.9bn ₩-1.1bn ₩-1.8bn
2026-08-27 ₩64,300 +₩0.8bn ₩-0.0bn ₩-0.8bn
2026-08-26 ₩63,300 ₩-5.7bn +₩12.6bn ₩-8.0bn
2026-08-25 ₩60,700 ₩-0.8bn +₩2.7bn ₩-1.9bn
2026-08-24 ₩59,800 +₩4.5bn ₩-1.9bn ₩-2.7bn
2026-08-21 ₩56,500 ₩-3.7bn ₩-1.5bn +₩5.6bn
2026-08-20 ₩62,600 ₩-3.9bn +₩5.9bn ₩-2.0bn
2026-08-19 ₩59,200 +₩1.7bn +₩2.6bn ₩-2.8bn
2026-08-18 ₩58,700 +₩1.3bn +₩2.7bn ₩-3.3bn
2026-08-14 ₩59,700 ₩-0.1bn ₩-1.3bn +₩1.5bn
2026-08-13 ₩60,400 +₩7.0bn +₩3.8bn ₩-11.4bn
2026-08-12 ₩55,700 +₩1.5bn ₩-0.8bn ₩-0.7bn
2026-08-11 ₩56,900 +₩2.9bn +₩0.0bn ₩-3.8bn
2026-08-10 ₩56,900 ₩-2.4bn +₩2.7bn ₩-2.1bn
2026-08-07 ₩54,100 ₩-0.5bn ₩-0.1bn +₩0.7bn
2026-08-06 ₩55,600 ₩-0.6bn +₩3.7bn ₩-3.1bn
2026-08-05 ₩53,100 ₩-0.1bn +₩1.1bn ₩-1.3bn
2026-08-04 ₩52,000 +₩4.7bn +₩6.0bn ₩-10.6bn
2026-08-03 ₩45,950 +₩0.0bn +₩0.6bn ₩-0.7bn
2026-07-31 ₩43,400 +₩0.7bn +₩0.6bn ₩-1.4bn
2026-07-30 ₩39,000 +₩0.7bn ₩-5.1bn +₩4.5bn
2026-07-29 ₩41,700 +₩4.5bn ₩-1.1bn ₩-3.3bn
2026-07-28 ₩45,200 ₩-1.1bn +₩0.4bn +₩1.5bn
2026-07-27 ₩47,500 +₩0.4bn ₩-0.4bn +₩0.0bn
2026-07-24 ₩46,600 +₩0.0bn ₩-1.4bn +₩1.6bn
2026-07-23 ₩49,650 ₩-0.3bn ₩-1.3bn +₩1.4bn
2026-07-22 ₩48,000 ₩-1.1bn ₩-3.3bn +₩4.3bn
2026-07-21 ₩48,150 +₩1.2bn ₩-1.9bn +₩0.3bn
2026-07-20 ₩49,250 ₩-0.4bn ₩-0.7bn +₩0.8bn
2026-07-16 ₩52,800 ₩-1.8bn +₩0.1bn +₩1.2bn
2026-07-15 ₩54,400 +₩4.5bn +₩0.2bn ₩-4.0bn
2026-07-14 ₩50,300 ₩-2.5bn ₩-2.1bn +₩4.3bn
2026-07-13 ₩55,200 ₩-1.9bn +₩1.4bn +₩0.5bn

Investor flows summary

Window Foreign (USD) Institutions Retail
1 day +₩3.0bn +$2M ₩-1.6bn ₩-2.2bn
5 days +₩4.7bn +$4M ₩-2.8bn ₩-3.2bn
20 days +₩17.3bn +$13M ₩-36.8bn +₩19.9bn

Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.

Frequently asked questions

Are foreign investors buying Hanall Biopharma stock?

Over the last 5 sessions foreign investors net bought ₩4.7bn ($4M) of Hanall Biopharma; over 60 sessions they net bought ₩43.7bn ($33M); since Jan 1, 2026 they net sold ₩25.7bn ($19M). Over 20 sessions the stock is the 34th largest foreign net purchase among 832 KOSPI stocks.

How much of Hanall Biopharma do foreign investors own?

Foreign investors own 4.46% of Hanall Biopharma's shares as of Oct 13, 2026, versus 4.75% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.

Who is on the other side — institutions or retail investors?

Over 20 sessions institutions net sold ₩36.8bn ($28M) and retail investors net bought ₩19.9bn ($15M) of Hanall Biopharma. Foreign buying is being met mainly by institutional selling.

Is Hanall Biopharma listed on KOSPI or KOSDAQ?

Hanall Biopharma (한올바이오파마) trades on KOSPI under KRX code 009420 in the Biotech & Pharma group, with a market capitalization of ₩2T ($1.6B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.

Annual financials

Fiscal year Revenue YoY Operating profit Net income
2023 ₩135bn ($101M) – ₩2bn ($2M) ₩4bn ($3M)
2024 ₩139bn ($104M) +3.00% ₩0bn ($0M) -₩2bn (-$1M)
2025 ₩155bn ($116M) +11.70% -₩1bn (-$1M) -₩6bn (-$4M)

Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.

← All foreign investor flows